David Kim is a Cardiology physician. ClinicalTrials.gov lists 15 registered studies matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Research metrics aren't shown for this record. Either we found no confident publication match for this name, or more than one physician shares the matched author record. We'd rather show nothing than someone else's numbers. Why? →
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
200 Hygeia Dr Ste 1360
Newark, DE 197132049
Telephone
302-623-1929Provider last certified this registry record 6 Aug 2021.
Clinical trials
- Return to Activity After Surgery for Lumbar Disc Herniation
Sponsor: Intrinsic Therapeutics
- Efficacy of a Dental Implant System for Immediate Restoration
Sponsor: Harvard Medical School (HMS and HSDM)
- Socket Preservation With BioHorizon's Striate+ Membrane and MinerOss X Plug
Sponsor: Harvard School of Dental Medicine
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
23 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- Medtronic, Inc.Program year202518 payments
- AOP Health US, LLCProgram year20251 payment
- Boston Scientific CorporationProgram year20255 payments
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Cardiovascular
78.4%Beta blocker23.5%Metoprolol Succinate56%Carvedilol31%Atenolol6%Metoprolol Tartrate5%Sotalol3%Part D<11 patientsStatin19.9%Atorvastatin Calcium65%Rosuvastatin Calcium30%Simvastatin3%Pravastatin Sodium3%Part D<11 patients+ 11 more classes in this area
Blood & clotting
18.5%Factor Xa inhibitor13.8%Eliquis70%Xarelto30%Part D≥74 patientsP2Y12 inhibitor2.2%Clopidogrel100%Part D≥20 patients+ 2 more classes in this area
Metabolism & gastrointestinal
3.1%SGLT2 inhibitor2%Jardiance100%Part D≥18 patientsProton pump inhibitor0.6%Omeprazole100%Part D<11 patients+ 1 more class in this area
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Similar KOLs
Other experts from the same institution or the same specialty.
Gregory Y.H. Lip
Medical University of Białystok
Mika Kivimäki
University of Helsinki
Salim Yusuf
Population Health Research Institute
Victoria Delgado
Institute of Molecular Bioimaging and Physiology
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”